RIABNI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RIABNI (RIABNI).
Rituximab is a chimeric murine/human monoclonal IgG1 kappa antibody that binds specifically to the CD20 antigen expressed on pre-B and mature B-lymphocytes. Upon binding, it mediates B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
| Metabolism | Rituximab is a monoclonal antibody metabolized via general protein catabolism; no specific metabolic pathway. |
| Excretion | RIABNI (rituximab-abbs) is a chimeric monoclonal antibody. Elimination occurs via nonspecific catabolism and target-mediated clearance. No significant renal or biliary excretion; <1% excreted unchanged in urine. Metabolism is primarily through proteolytic degradation to small peptides and amino acids. |
| Half-life | The terminal elimination half-life is approximately 22 days (range 6-52 days) in patients with rheumatoid arthritis. In B-cell non-Hodgkin lymphoma, median half-life is 8 days after first dose and 15-30 days after subsequent doses due to saturable clearance. Clinical context: prolonged half-life supports weekly or monthly dosing. |
| Protein binding | Rituximab-abbs binds specifically to CD20 antigen on B-cells; plasma protein binding is not relevant for monoclonal antibodies. No significant binding to other serum proteins. The molecule is primarily in the free form in circulation. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 3.0-5.0 L/kg. This large Vd reflects extensive distribution into tissues, including lymphoid organs and bone marrow, due to binding to CD20-positive cells. Central volume is ~2.7 L/m². |
| Bioavailability | RIABNI is administered intravenously only; bioavailability is 100% by this route. No oral formulation exists. |
| Onset of Action | Intravenous administration: depletion of peripheral B cells is detectable within 24 hours; clinical response in rheumatoid arthritis may be observed within 4-8 weeks. For oncology indications, tumor response may be seen after 2-4 cycles (weeks to months). |
| Duration of Action | B-cell depletion persists for 6-9 months after a single course (4 weekly doses) in rheumatoid arthritis, with gradual B-cell recovery starting at 6 months and returning to normal within 12 months. Duration of clinical response varies; in autoimmune indications, effects may last 6-12 months. |
1000 mg intravenously on days 1 and 15 of a 28-day cycle, then every 24 weeks or based on disease activity.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; use with caution in elderly patients due to higher risk of infections. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RIABNI (RIABNI).
| Breastfeeding | Rituximab is excreted in breast milk in low amounts; M/P ratio is approximately 1:800. Due to limited data, caution is advised. Consider discontinuing breastfeeding or drug, weighing importance of therapy to mother. |
| Teratogenic Risk | RIABNI (rituximab-abbs), a CD20-directed cytolytic antibody, is an IgG1 with potential transplacental transfer, increasing from second trimester. First trimester: limited data, theoretical risk of B-cell depletion. Second/third trimesters: risk of neonatal B-cell lymphopenia and immunosuppression; advise avoiding live vaccines in infants. |
■ FDA Black Box Warning
Fatal infusion reactions, severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), and hepatitis B reactivation have been reported.
| Serious Effects |
["Known hypersensitivity to rituximab or any component of the product."]
| Precautions | ["Infusion reactions: premedicate with antihistamines and corticosteroids.","Hepatitis B reactivation: screen all patients; monitor during and after therapy.","Progressive multifocal leukoencephalopathy (PML): discontinue if suspected.","Cardiac adverse reactions: monitor patients with pre-existing cardiac conditions.","Bowel obstruction: report in patients with NHL."] |
Loading safety data…
| Fetal Monitoring |
| Monitor for infusion reactions, infections. In pregnancy, consider fetal ultrasound for growth and anomalies. Neonatal monitoring for B-cell counts, immunoglobulin levels, and infection risk. |
| Fertility Effects | Rituximab may cause reversible B-cell depletion, but no evidence of permanent fertility impairment. Studies in animals show no adverse effects on fertility. |